Fredun Pharmaceuticals Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 28 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.6K Cr
Targeting 15% to 20% year-on-year revenue growth overall. Targeting 15% to 20% year-on-year revenue growth going forward.
From Fredun Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,435
Market Cap
₹2.6K Cr
P/E Ratio
57.6
How does Fredun Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Fredun Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Fredun Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹213 Cr, net profit ₹11 Cr.
Full financials →📊 Revenue & Sales Performance
- →Targeting 15% to 20% year-on-year revenue growth overall.
- →Ambition to double revenue and PAT within 3 to 4 years, aiming for INR 800+ crore top line and INR 90+ crore PAT.
- →Vintage business expected to grow around 15% to 18% annually, supported by 1,290 product registrations in the pipeline.
- →New age business, including Fredun Gx and pet care, targeted to reach INR 150 crore in next years with higher gross margins (above 50%).
- →Plan to eliminate low-margin products and improve cost efficiencies with expanded manufacturing capacity.
- →Anticipate growth from new age segments such as pet care, nutrition, and wellness.
- →Working capital improvements expected to stabilize cash flows and support growth sustainably.
- →Strong order book with confirmed orders covering a 6-month period supports steady growth visibility.
📈 Profitability & Margins
- →Targeting 15% to 20% year-on-year revenue growth going forward.
- →Aim to double revenue and PAT in the next 3 to 4 years, targeting INR 800+ crore top line and INR 90+ crore PAT.
- →EBITDA margins expected to improve as new age business (with above 50% gross margins) scales up.
- →New age business segments (pet care, nutrition, mobility, wellness) expected to grow at 35% to 40% CAGR.
- →Shift towards branded products and higher margin offerings to enhance profitability.
- →Expect cost efficiencies and continuous improvement to drive improved margins and profitability.
- →Debtors and inventory days expected to stabilize, supporting better cash flows and earnings visibility.
- →No bad debts historically; confident of sustaining profitable growth and cash flow improvements.
🏗️ Capital Expenditure Plans
- →Diagnostic center expansion: Planning to open a new diagnostic center in north Mumbai by end of the year; aiming to expand to multiple large cities over next 18 months.
- →Per center capex for diagnostic centers estimated around INR 6-8 crores.
- →Expansion of manufacturing capacity: Targeting to have one of the largest single-location plants in India within next 18-24 months to support new age business growth.
- →Continuous investment in creating efficiencies and manufacturing capabilities to support growth and margin expansion.
- →Strategic acquisition: Acquired One Pet Stop to access 4,000 pet customers and expand pet care ecosystem.
- →Future fundraising planned to support growth and capital requirements; no immediate pressure on funds due to current working capital debt structure.
💰 Fundraising & Capital Structure
- →The company is definitely planning a fundraise and will evaluate requirements soon.
- →No fixed timeline mentioned, but fundraising is expected in the coming months.
- →Currently, there is no long-term debt; most debt is working capital.
- →Even without raising funds in the next 1 to 6 months, growth is not expected to be hampered.
- →The company has successfully grown about 30% last financial year without raising funds.
- →Debt-equity ratio is around 1:1; the company is comfortable but open to equity infusion to support high growth plans.
📋 Order Book & Pipeline
- →Fredun Pharmaceuticals has a firm order book valued at around INR 200 crores.
- →These orders cover both export and local markets.
- →Orders from export markets are confirmed for a 6-month period.
- →Local market orders, including third-party orders, also generally cover a 6-month period.
- →The company does not record orders in its system unless they are confirmed.
- →This implies an assured order book of approximately two quarters for the vintage business and associated segments.
Key Metrics
Frequently Asked Questions
What were Fredun Pharmaceuticals Ltd Q1 FY26 results?
Targeting 15% to 20% year-on-year revenue growth overall. Targeting 15% to 20% year-on-year revenue growth going forward.
What is Fredun Pharmaceuticals Ltd share price analysis?
Fredun Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 57.6 with a market cap of ₹2,560 Cr. Investors should review the full earnings analysis for detailed insights.
Is Fredun Pharmaceuticals Ltd planning capital expenditure?
Diagnostic center expansion: Planning to open a new diagnostic center in north Mumbai by end of the year; aiming to expand to multiple large cities over next 18 months.
Keep Fredun Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.